Clinical efficacy and safety of polyethylene glycol 3350 versus liquid paraffin in the treatment of pediatric functional constipation by Rafati, MR. et al.
Clinical efficacy and safety of polyethylene glycol 3350 versus liquid 
paraffin in the treatment of pediatric functional constipation
*1Rafati MR., 2Karami H., 3Salehifar E., 1Karimzadeh A.
1Pharmaceutical  Sciences  Research  Center,  School  of  Pharmacy, 2Department  of  Pediatrics, 
School  of  Medicine, 3Department  of  Clinical  Pharmacy,  School  of  Pharmacy, Mazandaran 
University of Medical Sciences, Sari, Iran.
Received 4 Aug 2010; Revised 17 April 2011; Accepted 18 April 2011
ABSTRACT
Background and the purpose of the study: Functional constipation is prevalent in children. 
Recently polyethylene glycol has been introduced as an effective and safe drug to treat chronic 
constipation. There are only a few clinical trials on comparison of PEG and liquid paraffin in 
childhood constipation. The purpose of this study was to evaluate clinical efficacy and safety of 
PEG 3350 solution and liquid paraffin in the treatment of children with functional constipation 
in Sari Toba clinic during the period of 2008-2009.
Methods: Children with a history of functional constipation were subjects of this study. One 
hundred and sixty children of 2-12 years old with functional constipation were randomized in 
two PEG and paraffin treatment groups. Patients received either 1.0-1.5 g/kg/day PEG 3350 
or 1.0-1.5 ml/kg/day liquid paraffin for 4 months. Clinical efficacy was evaluated by stool and 
encopresis frequency/week and overall treatment success rate was compared in two groups.
Results  and  major  conclusion:  Compared with the baseline, defecation frequency/ week 
increased significantly and encopresis frequency meaningfully decreased in two groups during 
the period of the study. Patients using PEG 3350 had more success rate (mean: 95.3%±3.7) 
compared with the patients in paraffin group (mean: 87.2%±7.1) (p=0.087). Administration 
of PEG 3350 were associated with less adverse events than liquid paraffin. In conclusion in 
treatment of pediatric functional constipation, regarding clinical efficacy and safety, PEG 3350 
were at least as effective as liquid paraffin and but less adverse drug events.
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INTRODUCTION
Approximately 3% of general pediatric outpatient 
visits and 25% of pediatric gastroenterology 
consultations are related to perceived defecation 
disorders (1). More than 95% of children older 
than 1 year with constipation suffer from functional 
constipation  (2).  Liquid  paraffin  (mineral  oil)  is 
widely accepted and recommended as a fundamental 
component of regimens for the management of 
constipation in North America and Australia (3). 
Extensive experiences with long-term uses of mineral 
oil have shown its efficacy and safety (4) and North 
American Society for Pediatric Gastroenterology, 
Hepatology and Nutrition (NASPGN) clearly 
identify liquid paraffin as a medication of first choice 
in the management of pediatric constipation (3). 
This drug combines ease of titration with tolerability 
and sustained effect despite prolonged uses and 
make it attractive for use in childhood constipation 
encopresis (5). Mineral oil is not recommended 
for infants less than 1 year old due to the risk of 
aspiration and development of lipoid pneumonia. 
Some studies have shown PEG has at least equal 
efficacy  and  fewer  adverse  effects  in  comparison 
with lactulose (6, 7). A recent systematic review has 
demonstrated the efficacy of PEG as good as or even 
better than lactulose or milk of magnesia over a wide 
range of ages and treatment durations (8). There 
are only a few clinical trials on the comparison of 
PEG and liquid paraffin in childhood constipation. 
The purpose of this study was to evaluate clinical 
efficacy and safety of PEG 3350 solution and liquid 
paraffin in the treatment of children with functional 
constipation. 
METHODS 
Subjects
Patients eligible for enrolment were ambulatory 2 
to 12 years old children with a history of functional 
constipation (at least 3 months) defined as less than 
3 stools/week, more than 1 encopresis/week or 
palpable abdominal or rectal fecal mass on physical 
examination. The patients referred to Toba clinic 
154initially were examined and followed during the 
study by a pediatric gastroenterologist. 
Exclusion criteria were: Withdrawn the treatment 
during  the  first  month,  hypothyroidism,  Hirschsprung 
disease;  known  cardiac,  renal  and  neurologic 
disorders, any sign of organic causes, and history of 
colon surgery. At the time of enrolment, a full history 
details was obtained including pain or bleeding 
during defection, frequency of defecation, fecal 
impaction, and encopresis. Written informed consent 
was obtained from parents after full description of the 
study details. The ethics committee of Mazandaran 
University of Medical Sciences (MAZUMS) approved 
this open-labeled randomized study that accomplished 
in Sari Toba clinic affiliated to MAZUMS during the 
period of 2008-2009. At the beginning of the therapy, 
all patients and their parents were educated for 
appropriate diet, dairy consumption, toilet training 
and adverse drug reactions. Random table was used 
to randomize the patients in two groups. 
Study Protocol
Patients were randomly assigned to receive either 
1.0-1.5 g/kg/day PEG 3350 or 1.0-1.5 ml/kg/day 
liquid  paraffin  orally  for  4  months.  PEG  3350 
powder was prepared as a 40% solution to trust 
reliable to apply the pediatric dosing and to increase 
compliance and liquid paraffin was provided from 
a pharmaceutical factory. For rectal disimpaction, 
bisacodyl suppositories were applied at the beginning 
of the study. After the first physical exam, the patients 
were visited at least on the days of 7, 14, 30, 60, 90, 
and 120 during the treatment period, repeatedly. 
Assessment
Clinical  efficacy  was  evaluated  by  stool  and       
encopresis frequency/week and overall treatment 
success rate was compared in two groups. Patients 
that were withdrawn from the study due to lack of 
efficacy or adverse reaction of the drug placed in 
unsuccessful cases and remaining were considered 
as successful group. Adverse drug events were 
determined during examination or at the time of 
complain of patients and their parents.  
Statistical Analyses
The statistical analysis was performed using 
SPSS-16 software and results were expressed as 
means±SD. Means differences between two groups 
were compared by independent samples t-test. 
P-values less than 0.05 were considered statistically 
significant.  
RESULTS AND DISCUSSION
One hundred and sixty children 2-12 years old with 
functional constipation were included in this study. 
Since 2 patients dropped out in paraffin group, the 
final data were reported of a total 158 patients (80 
in the PEG and 78 in the paraffin groups). There 
was  no  significant  difference  with  regard  to  age, 
and baseline frequencies of stool, encopresis, fecal 
impaction, rectal pain or bleeding during defecation 
between two treatment groups Table 1.
Although all patients and their parents were educated 
for appropriate diet, dairy consumption and toilet 
training initially and during the study, the amount 
of patients’ compliance were not recorded and 
compared.
This randomized clinical trial demonstrated that 
both PEG 3350 and liquid paraffin were effective 
in increasing defecation frequency and decreasing 
encopresis significantly during the 4 month treatment 
period.  The  mean  defecation  rate  significantly 
increased in PEG group from 1.6 ± 0.8/week to           
7.0 ± 3.8/week and 1.4 ± .05/week to 6.3 ± 3.1/week 
in paraffin group (Table2). Patients using PEG and 
liquid paraffin had less encopresis in the 30th day of 
the treatment (from 27 cases to 12 and 28 cases to 10 
in two groups respectively, p>0.05). As a result, with 
regard to defecation and encopresis frequency, PEG 
3350 and liquid paraffin were equally effective. 
Success rates were compared at 30, 60, 90 and 120 
days after the beginning of the therapy and are shown 
in figure 1. A higher number of patients in the PEG 
group (mean: 95.3%±3.7) were treated compared 
with the paraffin group (mean: 87.2%±7.1) (p=0.087). 
Although the mean differences were not significant, 
the trend of success rate showed that larger sample 
size could demonstrate better efficacy.
For the significant number of children with chronic 
constipation, maintenance therapy may be essential 
for longer period to regulate bowel movements 
without difficulty. A few studies have been performed 
to compare PEG vs. paraffin with regards to clinical 
efficacy and safety.
A crossover randomized clinical trial in 37 patients 
 Variable     PEG 3350          Paraffin      P value  
Gender (male/female) 41/39      43/35 0.625
Age (month) 52.8±23.4     50.6±23.6 0.56  
Fecal impaction      42            40 0.94       
Rectal bleeding during defecation 11            13 0.61        
Pain during defecation                  71            70 0.84    
Table 1. Baseline characteristics of the patients.
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aged 2 to 16 years, PEG 3350 and lactulose increased 
stool frequency from 1.7±0.8/week to 14.8±1.4/week 
and 13.5±1.5/week respectively (6). Administration 
of PEG at the average dose of 1g/kg/day to 75 
children 1-24 months with constipation increased 
mean defecation frequency from 3.7±3.2/week to 
12.4±7.0/week in the initial 4 month of therapy 
(10). In a similar study, 74 children with chronic 
constipation, mentioned stool frequency increased 
significantly  with  PEG  (from  2.8±0.3/week  to 
9.9±0.7/week) (p<0.001) (11). Significant decrease 
in the mean encopresis frequency/week was found 
in a study in Netherland (7). Similarly Karami et al 
reported that PEG 4000 was more effective than oral 
paraffin to increase stool frequency (from 2.6±1.4/
week to 4.7±1.8/week and 3.0±1.5/week to 4.5±1.9/
week respectively) (12).
In a case control study (13), children with constipation 
were treated with PEG or milk of magnesia. During 
one year follow up, bowel movement frequency 
increased and soiling events decreased significantly 
in both groups. In another report PEG 3350 and 
lactulose were compared in 100 children 6 months to 
15 years with functional constipation for 8 weeks (7). 
It was found that 56% in PEG group were successfully 
treated compared to 29% in lactulose group and there 
were significant increase in the mean stool frequency/
week and decrease encopresis frequency/week in 
both groups. A 3-month study with 96 patients aged 
6-36 months showed the efficacy of PEG 4000 equal 
to or greater than lactulose (14).  
A 2-week crossover study using either PEG 3350 
or lactulose, reported that the success rate was 
significantly  higher  in  PEG  group  (84%)  than 
lactulose group (46%) (6). Also the treatment with 
PEG was more effective in terms of tolerability. 
Wang et al in their 2 weeks study have shown PEG 
4000 is meaningfully more effective than lactulose     
(70% vs. 40%) (15). A randomized study that 
compared PEG 3350 without electrolytes with milk 
of magnesia for constipation and fecal incontinence 
concluded that PEG and milk of magnesia were 
equally effective in long-term treatment. (16) 
All of adverse reactions (nausea, vomiting, 
flatulence, abdominal pain and dehydration), other 
than diarrhea, occurred more frequently in patients 
using  liquid  paraffin  compared  with  PEG  3350 
(p<0.05) (Table 3).. Rate of withdrawn for ADRs in 
those using paraffin were significantly higher than 
PEG 3350 (p<0.05).
In agreement with results of other reports (10, 13, 
17-18), in the present study, patients or their parents 
addressed mild adverse events and did not report any 
serious or new onset adverse reactions. In an eight 
weeks study period (7) PEG 3350 had no serious or 
significant adverse events and less adverse reactions 
Time
PEG 3350
(Mean±SD)
Paraffin
(Mean±SD)
P value      
At the beginning   1.6±0.8 1.4±0.5     0.69   
7th day  4.1±1.7       3.3±0.8   0.19
14th day 6.1±3.7 5.1±1.9 0.54  
30th day    7.0±3.8   6.3±3.1 0.70 
60th day 9.1±3.7 7.6±3.8        0.49      
90th day 8.9±3.8      7.6±3.4 0.51
120th day 8.7±2.9  7.5±3.2 0.58
Table 2. Number of defecation/week at the beginning and during the treatment in two groups.
Adverse reaction
PEG 3350
(Mean±SD)
Paraffin
(Mean±SD)
P value
Nausea         4.5±2.4 12.3±2.6 <0.01
Vomiting        0.2±0.4 2.5±1.9 0.014
Diarrhea        2±1.7 3.5±2.2 0.209
Flatulence       3.8±1.5 10.8±1.6 <0.01
 Abdominal pain 1.7±0.8 6.0±1.9 <0.01
Dehydration     0.0±0.0 0.5±0.5 0.049
Withdraw for ADR           0.3±0.5 1.5±1.1 0.035
Withdraw for no  efficacy       0.8±0.9 1.2±1.1 0.61
Need to additive drugs             1.2±1.1 2.2±1.5 0.22
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occurred compared with patients using lactulose. 
Although  it  has  been  reported  that  liquid  paraffin 
is more effective with fewer side effects, (17, 19), 
the present study showed that treatment of chronic 
constipation with PEG 3350 had less adverse events 
compared  with  liquid  paraffin.  These  results  were 
similar to others that reported PEG was safe for 
long  term  treatment  of  children  with  constipation.              
(16, 18).
CONCLUSION
The results of this study demonstrated that PEG 
3350 was at least as effective as liquid paraffin to 
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Figure 1. Rate of the success (%) in the course of the treatment for two groups.
treat pediatric functional constipation and with less 
adverse drug events. Reviewing the results of the 
present investigations and other studies with regard 
to  clinical  efficacy  and  safety,  revealed  that  PEG 
3350 can be drug of choice for treatment of chronic 
constipation in majority of children.
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